BMEABiomea Fusion, Inc. Common Stock
1.370USD-1.44%Mkt Cap: 99.30M $P/E: —3d ago
Biomea Fusion, Inc., a clinical-stage diabetes and obesity medicines company, focuses on the discovery and development of oral drugs to treat patients with diabetes and obesity. It's lead clinical program's drug candidat…
Industry Peers
BiotechnologyKey Statistics
Company
Market Cap99.30M $
Enterprise Value64.63M $
Revenue (TTM)—
Gross Profit—
Net Income (TTM)-61.80M $
Revenue/Share—
Last Price1.370 USD
Fiscal Year EndDec 2025
MR QuarterJun 2026
Employees37
CountryUS
SectorHealthcare
IndustryBiotechnology
ISIN—
Valuation
P/E (Trailing)—
P/E (Forward)-1.45
PEG—
EV/EBITDA-1.17
EV/Revenue—
P/S—
P/B8.14
EPS (TTM)-0.17
EPS (Forward)-0.94
52W Range
0.872024% of range2.990
52W High2.990 USD
52W Low0.8720 USD
Profitability
Gross Margin0.00%
Oper. Margin0.00%
EBITDA Margin0.00%
Profit Margin0.00%
ROE-209.11%
ROA-105.51%
Growth
Revenue Growth—
Earnings Growth—
Cash Flow & Leverage
Operating CF-70.37M $
CapEx (TTM)—
FCF Margin—
FCF Yield-27.99%
Net Debt-33.95M $
Net Debt/EBITDA0.61
Balance Sheet
Debt/Equity0.05
Current Ratio3.48
Quick Ratio3.32
Book Value/Sh0.1670 USD
Cash/Share0.4800 USD
Dividends
Fwd Div Rate—
Trail. Div Rate0.0000 USD
Div. Yield—
5Y Avg Yield—
Payout Ratio0.00%
Ex-Div Date—
Pay Date—
Analyst Consensus
Rating1.7 (Buy)
Strong BuyBuyHoldSellStr. Sell
Target (Mean)6.500 USD
Upside (mean)+374.5%
Target Range4.000 USD – 9.000 USD
$4.000+374.5% to mean$9.000
# Analysts6
Ownership
Shares Out.72.48M
Float67.63M
Insiders7.15%
Institutions40.02%
Short Interest
Short Ratio13.2d
Short % Float16.85%
Short % Out.13.82%
Shares Short10.02M
Short (prev mo.)13.83M
Technical
SMA 501.279 (+7.1%)
SMA 2001.352 (+1.3%)
Beta-0.30
S&P 52W Chg18.16%
Avg Vol (30d)558.50K
Avg Vol (10d)533.83K
Technical Indicators
RSI (14)61.5
MACD0.0172
MACD Signal-0.0003
MACD Hist.+0.0175
BB Upper1.379 USD
BB Middle1.269 USD
BB Lower1.159 USD
BB Width17.26%
ATR (14)0.0724 USD
Vol Ratio (20d)1.16x